Amphastar Pharma (AMPH) Tops Q1 EPS by 26c

Amphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of $1.04, $0.26 better than the analyst estimate of $0.78. Revenue for the quarter came in at $171.8 million versus the consensus estimate of $176.36 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• DA Davidson Reiterates Neutral Rating on Fastenal (FAST), Says Would Buy on 'Any Meaningful Retrenchment'
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M